[go: up one dir, main page]

SG71173A1 - 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives - Google Patents

1,3,8,-triaza-spiro[4,5]decan-4-on derivatives

Info

Publication number
SG71173A1
SG71173A1 SG1998005141A SG1998005141A SG71173A1 SG 71173 A1 SG71173 A1 SG 71173A1 SG 1998005141 A SG1998005141 A SG 1998005141A SG 1998005141 A SG1998005141 A SG 1998005141A SG 71173 A1 SG71173 A1 SG 71173A1
Authority
SG
Singapore
Prior art keywords
triaza
decan
spiro
derivatives
Prior art date
Application number
SG1998005141A
Other languages
English (en)
Inventor
Geo Adam
Andrea Cesure
Guido Galley
Francois Jenck
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG71173A1 publication Critical patent/SG71173A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Color Printing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG1998005141A 1997-12-05 1998-12-03 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives SG71173A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121427 1997-12-05

Publications (1)

Publication Number Publication Date
SG71173A1 true SG71173A1 (en) 2000-03-21

Family

ID=8227753

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1998005141A SG71173A1 (en) 1997-12-05 1998-12-03 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives

Country Status (29)

Country Link
US (1) US6043366A (zh)
JP (1) JP3366868B2 (zh)
KR (1) KR19990062800A (zh)
CN (1) CN1118467C (zh)
AR (1) AR016428A1 (zh)
AT (1) ATE212635T1 (zh)
AU (1) AU744338B2 (zh)
BR (1) BR9805297B1 (zh)
CA (1) CA2255171C (zh)
CO (1) CO4990965A1 (zh)
CZ (1) CZ399698A3 (zh)
DE (1) DE69803653T2 (zh)
DK (1) DK0921125T3 (zh)
ES (1) ES2170446T3 (zh)
HR (1) HRP980613A2 (zh)
HU (1) HUP9802807A3 (zh)
ID (1) ID21413A (zh)
IL (1) IL127399A0 (zh)
MA (1) MA26573A1 (zh)
NO (1) NO312161B1 (zh)
NZ (1) NZ333159A (zh)
PE (1) PE135299A1 (zh)
PL (1) PL330062A1 (zh)
PT (1) PT921125E (zh)
SG (1) SG71173A1 (zh)
TR (1) TR199802520A3 (zh)
TW (1) TW408123B (zh)
YU (1) YU55198A (zh)
ZA (1) ZA9811128B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
ATE396995T1 (de) * 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
US7566728B2 (en) * 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
NZ538307A (en) * 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2004058727A1 (en) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
CA2532059A1 (en) * 2003-05-23 2004-12-02 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
BRPI0609580A2 (pt) * 2005-03-22 2010-04-20 Hoffmann La Roche composto, polimorfo cristalino, processo para a sua manufatura, composições farmacêuticas que o contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização do composto
US20070299072A1 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
JP5727139B2 (ja) * 2006-11-28 2015-06-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ３−（３−アミノ−２−（ｒ）−ヒドロキシ−プロピル）−１−（４−フルオロ−フェニル）−８−（８−メチル−ナフタレン−１−イルメチル）−１，３，８−トリアザ−スピロ［４．５］デカン−４−オンの塩
BRPI0808025A2 (pt) 2007-03-01 2014-06-24 Mitsubishi Tanabe Pharma Corp Composto de benzimidazol e uso farmacêutico do mesmo
WO2008124209A1 (en) * 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
CN102459278A (zh) 2009-06-16 2012-05-16 默沙东公司 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮
JP7002335B2 (ja) * 2015-07-03 2022-01-20 エフ．ホフマン－ラ ロシュ アーゲー Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
GB1486546A (en) * 1975-02-28 1977-09-21 Yoshitomo Pharma Ind Ltd 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof
JPS51100084A (zh) * 1975-02-28 1976-09-03 Yoshitomi Pharmaceutical
JPS5934713B2 (ja) * 1976-01-05 1984-08-24 ウェルファイド株式会社 脂環式誘導体
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
GR73633B (zh) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
ATE67769T1 (de) * 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives

Also Published As

Publication number Publication date
CN1118467C (zh) 2003-08-20
NO312161B1 (no) 2002-04-02
AU9608798A (en) 1999-06-24
PL330062A1 (en) 1999-06-07
HU9802807D0 (en) 1999-02-01
CA2255171A1 (en) 1999-06-05
TR199802520A2 (xx) 1999-06-21
HRP980613A2 (en) 1999-08-31
JPH11228575A (ja) 1999-08-24
CN1222521A (zh) 1999-07-14
BR9805297B1 (pt) 2010-07-13
ZA9811128B (en) 1999-06-07
DE69803653T2 (de) 2002-08-29
DK0921125T3 (da) 2002-05-13
KR19990062800A (ko) 1999-07-26
ES2170446T3 (es) 2002-08-01
HUP9802807A3 (en) 2000-01-28
HUP9802807A2 (hu) 1999-08-30
ID21413A (id) 1999-06-10
ATE212635T1 (de) 2002-02-15
NO985684L (no) 1999-06-07
AR016428A1 (es) 2001-07-04
CZ399698A3 (cs) 1999-06-16
TR199802520A3 (tr) 1999-06-21
BR9805297A (pt) 2000-02-01
TW408123B (en) 2000-10-11
YU55198A (sh) 2001-12-26
AU744338B2 (en) 2002-02-21
NZ333159A (en) 2000-06-23
CO4990965A1 (es) 2000-12-26
NO985684D0 (no) 1998-12-04
PT921125E (pt) 2002-06-28
JP3366868B2 (ja) 2003-01-14
PE135299A1 (es) 2000-01-18
CA2255171C (en) 2009-09-29
IL127399A0 (en) 1999-10-28
DE69803653D1 (de) 2002-03-14
MA26573A1 (fr) 2004-12-20
US6043366A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
ZA977687B (en) Substituted 6,5-hetero-bicyclic derivatives
HK1019597A1 (en) Substituted 6, 6-hetero-bicyclic derivatives
ZA98570B (en) 8-substituted-1,3,8-triaza-spiro[4,5]decan-4-on derivatives
GB9702194D0 (en) Sulphonide derivatives
HUP0003642A3 (en) N-alkanoylphenylalanine derivatives
ZA987602B (en) N-alkanoylphenylalanine derivatives
HU9801168D0 (en) Triazinylaminostilbene derivatives
HU9802807D0 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives
IL134220A0 (en) 6,9-bridged erythromycin derivatives
IL134996A0 (en) 6,11-bridged erythromycin derivatives
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
IL132982A0 (en) Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
IL136500A0 (en) 1,4-diazacycloheptane derivatives
GB9715821D0 (en) Amidino-camptothecin derivatives
GB2321457B (en) 5-Aroylnaphthalene derivatives
GB9725541D0 (en) Amino-benzothiazole derivatives
GB9701628D0 (en) Imino-aza-anthracyclinone derivatives
HRP970162A2 (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
ZA983116B (en) Arylsecocholadiene derivatives
IL131159A0 (en) 4-Aminoethoxyindazole derivatives
GB9706753D0 (en) Aralkoxy-morphinan derivatives
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
ZA989848B (en) 6,11-bridged erythromycin derivatives